Loading
A phase 2 trial of Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer is a phase 2 interventional study registered as NCT05999994 by Eli Lilly and Company, with 105 participants planned, started 2020-01-22 and due to reach its primary completion in 2027-05. Interventions recorded: Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vinorelbine, Docetaxel, Gemcitabine and the tag pipeline.
Shares Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/